1. Li, Yun, Zhang, Jingjing, Cai, Ying, Xu, Yingjie, Huang, Masha. 2023. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer. In Biochemical and biophysical research communications, 658, 107-115. doi:10.1016/j.bbrc.2023.03.073. https://pubmed.ncbi.nlm.nih.gov/37030064/
2. Liu, Hao, Zhang, Zhenzhan, Zhen, Peilin, Zhou, Meijuan. 2021. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling. In Journal of immunology research, 2021, 6657012. doi:10.1155/2021/6657012. https://pubmed.ncbi.nlm.nih.gov/33506057/
3. Lee, Meng-Lin, Liang, Chao, Chuang, Cheng-Hsun, Liao, Kuang-Wen, Huang, Hsien-Da. 2022. A genome-wide association study for varicose veins. In Phlebology, 37, 267-278. doi:10.1177/02683555211069248. https://pubmed.ncbi.nlm.nih.gov/35099328/
4. Lee, Jungwhoi, Sim, Woogwang, Lee, Jungsul, Kim, Jae-Hoon. . VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma. In BMB reports, 57, 324-329. doi:. https://pubmed.ncbi.nlm.nih.gov/38649146/
5. Rossini, Lara, Hashimoto, Yuichi, Suzuki, Hiroaki, Matsuoka, Masaaki, Caricasole, Andrea. 2011. VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25, 1983-2000. doi:10.1096/fj.10-163535. https://pubmed.ncbi.nlm.nih.gov/21393573/
智鼠故事 
